MELATONIN AFTER 50: SEVEN MINUTES, AND A LABEL PROBLEM

Melatonin is the sleep supplement most people over 50 have already tried. It is also one of the few where a large pooled analysis, a professional guideline, and the label on the bottle all point in different directions — and the disagreement is more useful than any single number.

What the Pooled Data Actually Shows

The most cited meta-analysis on melatonin for primary sleep disorders pooled 19 randomized, placebo-controlled trials covering 1,683 subjects (Ferracioli-Oda, Qawasmi and Bloch, PLoS One 2013).

Three findings, at the size they were actually reported:

• Sleep onset latency — reduced by a weighted mean difference of 7.06 minutes (95% CI 4.37 to 9.75, p<0.001).
• Total sleep time — increased by 8.25 minutes (95% CI 1.74 to 14.75, p=0.013).
• Sleep quality — improved, standardized mean difference 0.22 (95% CI 0.12 to 0.32, p<0.001).

All three are statistically significant. All three are small. The authors say so themselves: the effects are modest, and the absolute benefit compared with placebo is smaller than for other pharmacological insomnia treatments. Their argument for melatonin having a role is not that it works better — it is that it has a relatively benign side-effect profile compared with those agents.

Two secondary findings from the same analysis are worth keeping. Trials with longer duration and higher doses showed greater effects on latency and total sleep time — but dose and duration did not significantly affect sleep quality. And the benefit did not appear to dissipate with continued use.

The Guideline That Says the Opposite

The American Academy of Sleep Medicine's 2017 clinical practice guideline for pharmacologic treatment of chronic insomnia in adults (Sateia et al., Journal of Clinical Sleep Medicine) reviewed individual agents under GRADE and issued a recommendation on each.

Its line on melatonin: clinicians are suggested not to use melatonin as a treatment for sleep onset or sleep maintenance insomnia in adults. That recommendation is graded WEAK — the same strength as most of the guideline's other recommendations, including the ones in favor of prescription agents. The guideline is explicit that a weak grade reflects lower certainty in the evidence, not a finding of ineffectiveness.

The same guideline landed the same way on tryptophan, valerian, diphenhydramine, and trazodone.

So one document reports a real but small effect, and the other says the evidence is not strong enough to recommend the agent for chronic insomnia. Both are describing the same literature. That is the honest state of it.

The One Trial Run Closest to This Audience

Most melatonin trials are in general adult or pediatric populations. One was run specifically in the age range this site writes for.

Wade and colleagues (Current Medical Research and Opinion, 2007) randomized 354 insomnia patients aged 55 to 80 to a 2 mg prolonged-release melatonin formulation or placebo, one tablet two hours before bedtime, over three weeks of double-blind treatment following a two-week placebo run-in. The responder rate — concomitant improvement in both sleep quality and morning alertness — was 26% on melatonin versus 15% on placebo (p=0.014). Sleep latency shortened by 24.3 minutes versus 12.9 minutes (p=0.028).

Read that carefully before generalizing it. The trial tested a specific proprietary prolonged-release prescription product, not an over-the-counter immediate-release supplement, and the study period was three weeks. The relevant number is also the gap, not the headline: 26% versus 15% means most participants in the treatment arm were not responders either.

The Problem That Has Nothing To Do With the Physiology

Erland and Saxena (Journal of Clinical Sleep Medicine, 2017) analyzed 31 commercial melatonin supplements by liquid chromatography.

Melatonin content ranged from 83% below to 478% above the labeled amount. Lot-to-lot variability within a single product ran as high as 465%. More than 71% of the supplements failed to meet their label claim within a 10% margin, and the variability did not track with manufacturer or product type. Separately, serotonin was detected in eight of the supplements, at 1 to 75 micrograms.

That is a finding about the supply chain, not about melatonin. But it has a direct practical consequence: in the United States, melatonin is sold as a dietary supplement rather than regulated as a drug, so a bottle labeled 3 mg is not a reliable statement of what you are taking — and neither is the next bottle of the same product. Any dose-response reasoning you do at home rests on a number that this analysis found is often not accurate.

The one lever available to a buyer is third-party testing — a USP Verified or NSF mark on the label — which does not make melatonin work better, but does address the question of whether the bottle contains what it says.

What Is Not in the Literature

I searched PubMed for randomized trials of melatonin in masters athletes and in older athletes. The masters-athlete search returned three records: a cross-sectional survey of supplement use among cyclists, runners and triathletes; a systematic review of drug treatments after mild traumatic brain injury; and a cell-culture study on adipocytes. None is a trial of melatonin in trained older athletes. The older-athlete sleep search returned nothing.

So: I could not find a randomized trial measuring melatonin's effect on sleep, recovery or performance in trained adults over 50. The trials above were run in insomnia patients and general adult populations. Whether any of it transfers to a masters athlete sleeping poorly the week of a race is not a question this evidence has answered.

The Honest Read

Melatonin is not a sedative and the pooled data does not describe it as one. What the trials measured is a small shift in how quickly people fall asleep and a small increase in total sleep time — on the order of minutes, not hours — with a side-effect profile the authors of both the meta-analysis and the guideline treat as favorable.

Where the evidence gets thinner is exactly where the marketing gets louder: high doses, indefinite use, and the assumption that the number on the bottle is the number in the capsule.

Sleep problems after 50 have a long list of causes that a supplement does not touch — including sleep apnea, which is a medical diagnosis and gets worse, not better, when the underlying cause goes unexamined. If your sleep is genuinely broken, that is a conversation with your physician, not a purchase.

Battle Hard. — Will Power